

Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/GC4E8FFDDF1AEN.html>

Date: March 2023

Pages: 114

Price: US\$ 3,480.00 (Single User License)

ID: GC4E8FFDDF1AEN

Abstracts

According to our (Global Info Research) latest study, the global Gastroesophageal Junction Adenocarcinoma Therapeutics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach.

This report is a detailed and comprehensive analysis for global Gastroesophageal Junction Adenocarcinoma Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Gastroesophageal Junction Adenocarcinoma Therapeutics market size and forecasts, in consumption value (\$ Million), 2018-2029

Global Gastroesophageal Junction Adenocarcinoma Therapeutics market size and forecasts by region and country, in consumption value (\$ Million), 2018-2029

Global Gastroesophageal Junction Adenocarcinoma Therapeutics market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2018-2029

Global Gastroesophageal Junction Adenocarcinoma Therapeutics market shares of main players, in revenue (\$ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Gastroesophageal Junction Adenocarcinoma Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Gastroesophageal Junction Adenocarcinoma Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene and Bristol-Myers Squibb, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Gastroesophageal Junction Adenocarcinoma Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Drug

Surgery

Chemotherapy

Targeted Therapy

Market segment by Application

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Market segment by players, this report covers

Astellas Pharmaceuticals

AstraZeneca

Bayer

Beigene

Bristol-Myers Squibb

Daichii Sankyo

Elevar Therapeutics

Eli Lilly

FivePrime Therapeutics

Incyte

Macrogenics

Merck Co

Ono Pharmaceuticals

Roche

Taiho Pharmaceuticals

Zai Labs

ZymeWorks

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Gastroesophageal Junction Adenocarcinoma Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Gastroesophageal Junction Adenocarcinoma Therapeutics, with revenue, gross margin and global market share of Gastroesophageal Junction Adenocarcinoma Therapeutics from 2018 to 2023.

Chapter 3, the Gastroesophageal Junction Adenocarcinoma Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by

landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Gastroesophageal Junction Adenocarcinoma Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Gastroesophageal Junction Adenocarcinoma Therapeutics.

Chapter 13, to describe Gastroesophageal Junction Adenocarcinoma Therapeutics research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Gastroesophageal Junction Adenocarcinoma Therapeutics

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Gastroesophageal Junction Adenocarcinoma Therapeutics by Type

1.3.1 Overview: Global Gastroesophageal Junction Adenocarcinoma Therapeutics

Market Size by Type: 2018 Versus 2022 Versus 2029

1.3.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type in 2022

1.3.3 Drug

1.3.4 Surgery

1.3.5 Chemotherapy

1.3.6 Targeted Therapy

1.4 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market by Application

1.4.1 Overview: Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029

1.4.2 Hospital Pharmacy

1.4.3 Retail Pharmacy

1.4.4 Online Pharmacy

1.5 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size & Forecast

1.6 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast by Region

1.6.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

1.6.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region, (2018-2029)

1.6.3 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)

1.6.4 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)

1.6.5 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)

1.6.6 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Astellas Pharmaceuticals

2.1.1 Astellas Pharmaceuticals Details

2.1.2 Astellas Pharmaceuticals Major Business

2.1.3 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

2.1.4 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 Astellas Pharmaceuticals Recent Developments and Future Plans

2.2 AstraZeneca

2.2.1 AstraZeneca Details

2.2.2 AstraZeneca Major Business

2.2.3 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

2.2.4 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 AstraZeneca Recent Developments and Future Plans

2.3 Bayer

2.3.1 Bayer Details

2.3.2 Bayer Major Business

2.3.3 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

2.3.4 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Bayer Recent Developments and Future Plans

2.4 Beigene

2.4.1 Beigene Details

2.4.2 Beigene Major Business

2.4.3 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

2.4.4 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Beigene Recent Developments and Future Plans

2.5 Bristol-Myers Squibb

2.5.1 Bristol-Myers Squibb Details

- 2.5.2 Bristol-Myers Squibb Major Business
- 2.5.3 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- 2.5.4 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.6 Daichii Sankyo
 - 2.6.1 Daichii Sankyo Details
 - 2.6.2 Daichii Sankyo Major Business
 - 2.6.3 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.6.4 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 Daichii Sankyo Recent Developments and Future Plans
- 2.7 Elevar Therapeutics
 - 2.7.1 Elevar Therapeutics Details
 - 2.7.2 Elevar Therapeutics Major Business
 - 2.7.3 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.7.4 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 Elevar Therapeutics Recent Developments and Future Plans
- 2.8 Eli Lilly
 - 2.8.1 Eli Lilly Details
 - 2.8.2 Eli Lilly Major Business
 - 2.8.3 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.8.4 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.8.5 Eli Lilly Recent Developments and Future Plans
- 2.9 FivePrime Therapeutics
 - 2.9.1 FivePrime Therapeutics Details
 - 2.9.2 FivePrime Therapeutics Major Business
 - 2.9.3 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.9.4 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 FivePrime Therapeutics Recent Developments and Future Plans
- 2.10 Incyte

- 2.10.1 Incyte Details
- 2.10.2 Incyte Major Business
- 2.10.3 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- 2.10.4 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 2.10.5 Incyte Recent Developments and Future Plans
- 2.11 Macrogenics
 - 2.11.1 Macrogenics Details
 - 2.11.2 Macrogenics Major Business
 - 2.11.3 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.11.4 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.11.5 Macrogenics Recent Developments and Future Plans
- 2.12 Merck Co
 - 2.12.1 Merck Co Details
 - 2.12.2 Merck Co Major Business
 - 2.12.3 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.12.4 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.12.5 Merck Co Recent Developments and Future Plans
- 2.13 Ono Pharmaceuticals
 - 2.13.1 Ono Pharmaceuticals Details
 - 2.13.2 Ono Pharmaceuticals Major Business
 - 2.13.3 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.13.4 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.13.5 Ono Pharmaceuticals Recent Developments and Future Plans
- 2.14 Roche
 - 2.14.1 Roche Details
 - 2.14.2 Roche Major Business
 - 2.14.3 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
 - 2.14.4 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.14.5 Roche Recent Developments and Future Plans

2.15 Taiho Pharmaceuticals

2.15.1 Taiho Pharmaceuticals Details

2.15.2 Taiho Pharmaceuticals Major Business

2.15.3 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma

Therapeutics Product and Solutions

2.15.4 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma

Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.15.5 Taiho Pharmaceuticals Recent Developments and Future Plans

2.16 Zai Labs

2.16.1 Zai Labs Details

2.16.2 Zai Labs Major Business

2.16.3 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

2.16.4 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.16.5 Zai Labs Recent Developments and Future Plans

2.17 ZymeWorks

2.17.1 ZymeWorks Details

2.17.2 ZymeWorks Major Business

2.17.3 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

2.17.4 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.17.5 ZymeWorks Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Gastroesophageal Junction Adenocarcinoma Therapeutics by Company Revenue

3.2.2 Top 3 Gastroesophageal Junction Adenocarcinoma Therapeutics Players Market Share in 2022

3.2.3 Top 6 Gastroesophageal Junction Adenocarcinoma Therapeutics Players Market Share in 2022

3.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Overall Company Footprint Analysis

3.3.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Region

Footprint

3.3.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Company Product Type Footprint

3.3.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value and Market Share by Type (2018-2023)

4.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application (2018-2023)

5.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)

6.2 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)

6.3 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country

6.3.1 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)

6.3.2 United States Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

6.3.3 Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

6.3.4 Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

7 EUROPE

7.1 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)

7.2 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)

7.3 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country

7.3.1 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)

7.3.2 Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

7.3.3 France Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

7.3.5 Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

7.3.6 Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)

8.3 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region

8.3.1 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Region (2018-2029)

8.3.2 China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

8.3.3 Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

8.3.4 South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

8.3.5 India Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

8.3.7 Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

9.1 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)

9.2 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)

9.3 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country

9.3.1 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)

9.3.2 Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

9.3.3 Argentina Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country

10.3.1 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)

10.3.2 Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

10.3.4 UAE Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

- 11.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Drivers
- 11.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Restraints
- 11.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Trends Analysis
- 11.4 Porters Five Forces Analysis
 - 11.4.1 Threat of New Entrants
 - 11.4.2 Bargaining Power of Suppliers
 - 11.4.3 Bargaining Power of Buyers
 - 11.4.4 Threat of Substitutes
 - 11.4.5 Competitive Rivalry
- 11.5 Influence of COVID-19 and Russia-Ukraine War
 - 11.5.1 Influence of COVID-19
 - 11.5.2 Influence of Russia-Ukraine War

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Industry Chain
- 12.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Upstream Analysis
- 12.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Midstream Analysis
- 12.4 Gastroesophageal Junction Adenocarcinoma Therapeutics Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
- Table 4. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
- Table 5. Astellas Pharmaceuticals Company Information, Head Office, and Major Competitors
- Table 6. Astellas Pharmaceuticals Major Business
- Table 7. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 8. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 9. Astellas Pharmaceuticals Recent Developments and Future Plans
- Table 10. AstraZeneca Company Information, Head Office, and Major Competitors
- Table 11. AstraZeneca Major Business
- Table 12. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 13. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 14. AstraZeneca Recent Developments and Future Plans
- Table 15. Bayer Company Information, Head Office, and Major Competitors
- Table 16. Bayer Major Business
- Table 17. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 18. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 19. Bayer Recent Developments and Future Plans
- Table 20. Beigene Company Information, Head Office, and Major Competitors
- Table 21. Beigene Major Business
- Table 22. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 23. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue

(USD Million), Gross Margin and Market Share (2018-2023)

Table 24. Beigene Recent Developments and Future Plans

Table 25. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors

Table 26. Bristol-Myers Squibb Major Business

Table 27. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 28. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 29. Bristol-Myers Squibb Recent Developments and Future Plans

Table 30. Daichii Sankyo Company Information, Head Office, and Major Competitors

Table 31. Daichii Sankyo Major Business

Table 32. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 33. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 34. Daichii Sankyo Recent Developments and Future Plans

Table 35. Elevar Therapeutics Company Information, Head Office, and Major Competitors

Table 36. Elevar Therapeutics Major Business

Table 37. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 38. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 39. Elevar Therapeutics Recent Developments and Future Plans

Table 40. Eli Lilly Company Information, Head Office, and Major Competitors

Table 41. Eli Lilly Major Business

Table 42. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 43. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 44. Eli Lilly Recent Developments and Future Plans

Table 45. FivePrime Therapeutics Company Information, Head Office, and Major Competitors

Table 46. FivePrime Therapeutics Major Business

Table 47. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 48. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

- Table 49. FivePrime Therapeutics Recent Developments and Future Plans
- Table 50. Incyte Company Information, Head Office, and Major Competitors
- Table 51. Incyte Major Business
- Table 52. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 53. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 54. Incyte Recent Developments and Future Plans
- Table 55. Macrogenics Company Information, Head Office, and Major Competitors
- Table 56. Macrogenics Major Business
- Table 57. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 58. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 59. Macrogenics Recent Developments and Future Plans
- Table 60. Merck Co Company Information, Head Office, and Major Competitors
- Table 61. Merck Co Major Business
- Table 62. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 63. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 64. Merck Co Recent Developments and Future Plans
- Table 65. Ono Pharmaceuticals Company Information, Head Office, and Major Competitors
- Table 66. Ono Pharmaceuticals Major Business
- Table 67. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 68. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 69. Ono Pharmaceuticals Recent Developments and Future Plans
- Table 70. Roche Company Information, Head Office, and Major Competitors
- Table 71. Roche Major Business
- Table 72. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
- Table 73. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 74. Roche Recent Developments and Future Plans
- Table 75. Taiho Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 76. Taiho Pharmaceuticals Major Business

Table 77. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 78. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 79. Taiho Pharmaceuticals Recent Developments and Future Plans

Table 80. Zai Labs Company Information, Head Office, and Major Competitors

Table 81. Zai Labs Major Business

Table 82. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 83. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 84. Zai Labs Recent Developments and Future Plans

Table 85. ZymeWorks Company Information, Head Office, and Major Competitors

Table 86. ZymeWorks Major Business

Table 87. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions

Table 88. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 89. ZymeWorks Recent Developments and Future Plans

Table 90. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (USD Million) by Players (2018-2023)

Table 91. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Share by Players (2018-2023)

Table 92. Breakdown of Gastroesophageal Junction Adenocarcinoma Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)

Table 93. Market Position of Players in Gastroesophageal Junction Adenocarcinoma Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022

Table 94. Head Office of Key Gastroesophageal Junction Adenocarcinoma Therapeutics Players

Table 95. Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Company Product Type Footprint

Table 96. Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Company Product Application Footprint

Table 97. Gastroesophageal Junction Adenocarcinoma Therapeutics New Market Entrants and Barriers to Market Entry

Table 98. Gastroesophageal Junction Adenocarcinoma Therapeutics Mergers, Acquisition, Agreements, and Collaborations

Table 99. Global Gastroesophageal Junction Adenocarcinoma Therapeutics

Consumption Value (USD Million) by Type (2018-2023)

Table 100. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Share by Type (2018-2023)

Table 101. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Forecast by Type (2024-2029)

Table 102. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2023)

Table 103. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Forecast by Application (2024-2029)

Table 104. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 105. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 106. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 107. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 108. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 109. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 110. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 111. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 112. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 113. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 114. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 115. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 116. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 117. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 118. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 119. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 120. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 121. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 122. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 123. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 124. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 125. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 126. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 127. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 128. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 129. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 130. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 131. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 132. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 133. Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 134. Gastroesophageal Junction Adenocarcinoma Therapeutics Raw Material

Table 135. Key Suppliers of Gastroesophageal Junction Adenocarcinoma Therapeutics Raw Materials

List Of Figures

LIST OF FIGURES

- Figure 1. Gastroesophageal Junction Adenocarcinoma Therapeutics Picture
- Figure 2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type in 2022
- Figure 4. Drug
- Figure 5. Surgery
- Figure 6. Chemotherapy
- Figure 7. Targeted Therapy
- Figure 8. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 9. Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application in 2022
- Figure 10. Hospital Pharmacy Picture
- Figure 11. Retail Pharmacy Picture
- Figure 12. Online Pharmacy Picture
- Figure 13. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 14. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 15. Global Market Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
- Figure 16. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Region (2018-2029)
- Figure 17. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Region in 2022
- Figure 18. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 19. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 20. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 21. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)
- Figure 22. Middle East and Africa Gastroesophageal Junction Adenocarcinoma

Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 23. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Share by Players in 2022

Figure 24. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 25. Global Top 3 Players Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share in 2022

Figure 26. Global Top 6 Players Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share in 2022

Figure 27. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Share by Type (2018-2023)

Figure 28. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share Forecast by Type (2024-2029)

Figure 29. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Share by Application (2018-2023)

Figure 30. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Share Forecast by Application (2024-2029)

Figure 31. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 32. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 33. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 34. United States Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 35. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 36. Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 37. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 38. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 39. Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 40. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 41. France Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 42. United Kingdom Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 43. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 44. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 45. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 46. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 47. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 48. China Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 49. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 50. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 51. India Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 52. Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 53. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 54. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 55. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 56. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 57. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 58. Argentina Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 59. Middle East and Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 60. Middle East and Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 61. Middle East and Africa Gastroesophageal Junction Adenocarcinoma

Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 62. Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 63. Saudi Arabia Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 64. UAE Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 65. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Drivers

Figure 66. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Restraints

Figure 67. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Trends

Figure 68. Porters Five Forces Analysis

Figure 69. Manufacturing Cost Structure Analysis of Gastroesophageal Junction Adenocarcinoma Therapeutics in 2022

Figure 70. Manufacturing Process Analysis of Gastroesophageal Junction Adenocarcinoma Therapeutics

Figure 71. Gastroesophageal Junction Adenocarcinoma Therapeutics Industrial Chain

Figure 72. Methodology

Figure 73. Research Process and Data Source

I would like to order

Product name: Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/GC4E8FFDDF1AEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC4E8FFDDF1AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

